T-Therapeutics Ltd
Ben Grimshaw's work experience includes:
- Director, TCR Pipeline at T-Therapeutics Ltd starting in November 2022 (current role).
- Consultant and Founder at Evolve Labs Ltd since September 2022 (current role), providing client-focused support for lab and office set up and fit-outs.
- Head of Research and Operations at Clover Biopharmaceuticals from July 2021 to October 2022.
- Senior Research Scientist I at Kymab Ltd from January 2021 to July 2021.
- Research Scientist II at Kymab Ltd from January 2018 to January 2021.
- Research Scientist I at Kymab Ltd from June 2015 to January 2018.
- Director at SOUTH CAMBS GOSPEL TRUST from September 2016 to May 2020.
- PhD Student at University College London from October 2010 to July 2015.
- Associate Scientist II at MedImmune from November 2013 to June 2015.
- Senior Ambassador at University of Manchester from October 2009 to June 2010.
- Healthcare Assistant at Alliance Boots from September 2004 to January 2007, involved in pre-packing prescription drugs and working in customer service.
Ben Grimshaw completed their education from 2000 to 2007 at Dartford Grammar School for Boys, where they earned an International Baccalaureate Diploma & GCSEs in a secondary school field of study. Ben then pursued a Bachelor of Science degree in Medical Biochemistry from The University of Manchester from 2007 to 2010, specializing in Biological and Biomedical Sciences. Following that, they attended UCL from 2010 to 2015, where they obtained a Doctor of Philosophy (PhD) in Molecular Biology. In addition to their formal education, Ben Grimshaw obtained a certification in Goal Setting: Objectives and Key Results (OKRs) from LinkedIn in March 2022.
This person is not in any teams
T-Therapeutics Ltd
T-Therapeutics is a venture-backed company on a mission to unlock the power of T cells to treat chronic and infectious diseases. Based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine, T-Therapeutics has secured significant investment from a blue-chip syndicate of investors to support its drug discovery efforts and prepare candidates for clinical development. T-Therapeutics was founded in 2022, and we are at the very beginning of our journey to develop transformative T cell derived medicines. To realise our ambition, we are currently building facilities, recruiting staff, and establishing our research operations.